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Abstract 
Background  
The majority of patients with human papillomavirus (HPV)-associated oropharyngeal 
squamous cell carcinoma (OpSCC) have favourable survival outcomes, but a 
significant minority of individuals will die of their disease. There are currently no 
definitive criteria to identify HPV-associated OpSCC patients with poor outcome. 
Recent reports suggest that quantitative evaluation of T-cell subpopulations in 
OpSCC may be of prognostic value, but the methods used have limited utility in a 
clinical diagnostic setting. We sought therefore to determine the clinical prognostic 
utility of tumour-infiltrating lymphocyte (TIL) evaluation in HPV-associated OpSCC 
within the context of a diagnostic histopathology setting. 
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Methods 
Representative diagnostic haematoxylin and eosin (H&E) stained slides from 232 
consecutive HPV-associated OpSCC patients were classified as containing a high 
(TILHi; diffuse, lymphocytes in >80% of tumour and stroma), moderate (TILMod; 
patchy, present in 20-80% of tumour and stroma) or low (TILLo; sparse or absent, 
present in <20% of tumour and stroma). Inter-observer reliability was assessed, and 
TILs category was then correlated with overall survival (OS) and disease-free 
survival (DFS). 
Results 
Univariate and multivariate analysis showed a statistically significant difference in 
overall and disease-free survival estimates when TILHi and TILMod groups were 
compared with TILLo patients (p<0.0001 TILHi vs TILLo, p<0.0001 TILMod vs TILLo). 
Statistical significance was retained when TILHi and TILMod were grouped into a 
single category (TILHi) and compared to TILLo (p<0.0001). 
Conclusion 
We demonstrate the prognostic utility of TILs in HPV-associated OpSCC in clinical 
practice. A binary system classifying HPV-associated OpSCC into TILHi and TILLo  on 
routine H&E staining stratifies patients into potentially favourable and unfavourable 
survival outcomes, respectively. 
 
Keywords:  
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Background 
The dramatic rise in the incidence of oropharyngeal squamous cell carcinoma 
(OpSCC) in Europe and North America in the past two decades is attributable to 
high-risk types of human papillomavirus (HPV). In parallel with this striking 
epidemiological trend is the observation that patients with HPV-associated OpSCC 
have significantly improved overall- and disease-free survival outcomes compared to 
site- and stage-matched HPV-negative tumours1. While the majority of patients with 
HPV-associated OpSCC have favourable survival, a significant minority of these 
patients experience treatment resistance resulting in poor outcomes2, 3. 
Treatment failure in HPV-associated OpSCC is likely to be multifactorial, but 
emerging data suggest that the tumour immune microenvironment is likely to 
influence clinical outcomes. Recently, several studies utilising lymphocyte 
subpopulation-specific detection techniques have demonstrated a positive 
correlation between tumour-infiltrating lymphocytes (TILs) and improved survival in 
HPV-associated OpSCC 4-9. Within the context of a clinical histopathology setting 
from a single institution cohort, we sought to retrospectively validate the prognostic 
utility of TILs in HPV-associated OpSCC using diagnostic haematoxylin and eosin 
(H&E) stained sections.  
 
Materials and methods 
Consecutive patients diagnosed with HPV-associated OpSCC in the Department of 
Head and Neck Pathology, Guys’ & St Thomas’ NHS Foundations Trust between 
January 2005 and December 2017 were retrospectively identified from pathology 
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databases by members of the responsible clinical team, in compliance with the UK 
Data Protection Act. HPV testing was undertaken at the time of diagnosis according 
to current guidelines10. p16 immunohistochemistry (clone E6H4, CINtec, Roche, UK) 
was performed on an automated platform (Benchmark Ultra, Ventana Medical 
Systems, USA) according to manufacturer’s instruction as previously described11. 
OpSCCs demonstrating strong and diffuse nuclear and cytoplasmic positivity in 
>70% of tumour cells were then subject to high-risk HPV testing by DNA in-situ 
hybridisation (INFORM Family III, Roche, UK) according to manufacturer’s 
instruction as previously described11. Only OpSCCs demonstrating positivity for both 
p16 immunohistochemistry and high-risk HPV DNA by in-situ hybridisation were 
included in this study. TILs were evaluated on at least one representative whole-
mount diagnostic H&E slide from the primary tumour. Two pathologists (KR and ST) 
independently scored TILs according to a ternary classification system as described 
by Ward and colleagues6. Lymphocytes present within tumour nests/sheets, in the 
stromal component between tumour nests and in the normal lymphoid component of 
the tonsil and base of tongue were included. Any lymphocytes beyond the tumour 
invasive front, plasma cells and neutrophils were excluded from TILs assessment. 
Whole-section area was then categorised as high (TILHi; diffuse, present in >80% of 
tumour and stroma), moderate (TILMod; patchy, present in 20-80% of tumour and 
stroma) or low (TILLo; sparse or absent, present in <20% of tumour and stroma). We 
then also reclassified all tumours using a binary system as TILHi (diffuse or patchy, 
present in >20% of tumour and stroma) or TILLo (sparse or absent, present in <20% 
of tumour and stroma). Representative photomicrographs of TILHi and TILLo are 
demonstrated in Figure 1. Discordant categorisation was resolved in a consensus 
meeting between three pathologists (KR, AS and ST). Patient demographics, overall 
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survival (OS) and disease-free survival (DFS) were obtained from patient records 
and anonymised. Inter-rater agreement and survival estimate analyses were 
calculated using SPSS for Windows version 25 (IBM, Portsmouth, UK). Kappa and 
weighted kappa statistics, Kaplan-Meier log rank and Cox proportional hazard 
regression analyses were used to evaluate inter-rater reliability, univariate survival 
and multivariate survival, respectively.  
 
Results 
Slides of incisional biopsies or diagnostic tonsillectomies from 232 retrospectively 
identified primary HPV-associated OpSCCs were available for TILs evaluation. 
There were 188 males and 44 females (M:F=4.3:1) with a mean age of 59 years 
(range 35-83 years). Staging data were available for 224 patients and were as 
follows: T1=52, T2=87, T3=30, T4=55; N0=24, N1=19, N2a=34, N2b=90, N2c=43, 
N3=14; M0=216, M1=8). All patients received primary radiotherapy or 
chemoradiotherapy. 
The inter-rater kappa scores using the ternary and binary systems were 0.72 
(weighted) and 0.87, respectively. Following consensus classification using the 
ternary system, there were 104 (44.8%), 97 (41.8%) and 31 (13.4%) tumours 
categorised as TILHi, TILMod and TILLo, respectively. Using the binary system, there 
were 201 (86.6%) TILHi and 31 (13.4%) TILLo tumours. 
Using the ternary system, the mean OS estimates were 55.8 (95%CI: 53.2-58.4), 
52.1 (95%CI:48.5-55.7) and 37.4 (95%CI:28.8-46.0) months for TILHi, TILMod and 
TILLo, respectively. There was a statistically significant difference in OS estimates 
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when TILHi and TILMod groups were compared with TILLo patients (p<0.0001 TILHi vs 
TILLo, p<0.0001 TILMod vs TILLo). However, differences in OS estimates did not reach 
statistical significance when TILHi and TILMod groups were compared (p=0.071, 
Figure 2A). Mean DFS estimates were 58.8 (95%CI: 57.5-60.2), 53.8 (95%CI:50.4-
57.2) and 44.8 (95%CI:35.9-53.7) months for TILHi, TILMod and TILLo, respectively. 
There was a statistically significant difference in DFS estimates between all three 
groups (p<0.0001 TILHi vs TILLo, p=0.025 TILMod vs TILLo, p=0.008 TILHi vs TILMod 
Log Rank, Figure 2B). After adjusting for age, gender, T, N and M, there was a 
significant difference (p=0.006) between TILMod and TILLo for OS. Those with TILLo 
were 3.41 times more likely to not survive compared to those with TILMod (Hazard 
Ratio 3.41, 95%CI:1.42-8.15). There was no significant difference between TILHi and 
TILMod (p=0.129). For DFS, there was a significant difference (p=0.003) between 
TILLo and TILMod. Those with TILLo were 5.21 times more likely to not survive 
compared to those with TILMod (Hazard Ratio 5.21, 95%CI:1.74-15.62). There was no 
significant difference between TILHi and TILMod (p=0.154). 
Using the binary system, mean OS estimates were 54.1 (95%CI:51.8-56.3) and 37.4 
(95%CI:28.8-46.0) months for TILHi and TILLo, respectively (p<0.0001, Log Rank; 
Figure 2C). Mean DFS estimates were 56.4 (95%CI:54.6-58.2) and 44.4 
(95%CI:35.9-53.7) months for TILHi and TILLo, respectively p<0.0001, Figure 2D).  
After adjusting for age, gender, T, N and M there was a significant difference 
(p<0.0001) between TILHi and TILLo for OS. Those with TILHi were 4.55 times more 
likely to survive compared to those with TILLo (Hazard Ratio 0.22, 95%CI:0.10-0.51). 
For DFS, there was a significant difference (p<0.0001) between TILHi and TILLo for 
DFS. Those with TILHi were 7.14 times more likely to survive compared to those with 
TILLo (Hazard Ratio 0.14, 95%CI:0.05-0.42). 
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Discussion 
Calls for the introduction of treatment de-intensification regimens in HPV-associated 
OpSCC is founded on robust evidence that patients with this disease have improved 
overall- and disease-specific survival compared to site and stage-matched 
individuals. Despite this observation, approximately 20% of patients with HPV-
associated OpSCC are estimated to die of their disease and for whom treatment de-
intensification would be inappropriate3. There is therefore a need to refine inclusion 
criteria in de-intensification clinical trials beyond HPV status alone. 
Against this background, emerging evidence from several groups utilising 
quantitative and semi-quantitative methods for evaluating T-cell subpopulations raise 
the possibility that TILs may act as a potential prognostic biomarker in HPV-
associated OpSCC5-9, 12. Interestingly, Ward et al demonstrated that for purposes of 
prognostication, subjective evaluation of TILs on H&E stained sections performed 
equally well as more complex quantification of CD3, CD4, CD8, and FoxP3 T cell 
subpopulations6. In accordance with the work of Ward et al., our study also showed 
that TILs assessment on H&E sections has significant prognostic value and therefore 
overcomes the need for further ancillary testing. Within the context of routine clinical 
diagnostic practice, less complex prognostic tests are more likely to be adopted in 
view of cost and turnaround time benefits. 
Unlike the study by Ward et al, there was no statistically significant difference in 
overall survival between the TILHi and TILMod in our study cohort, an observation 
which may be explained, at least in part, by the subjective nature of TILs scoring. In 
our study, a statistically significant difference (p<0.0001) in overall survival remained 
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when TILHi and TILMod were group together and compared with TILLo. Binary 
classification systems are likely to be of greater clinical utility compared to ternary 
scoring systems since treatment protocols are more difficult to define in any 
‘intermediate’ group. 
Inter-observer reproducibility is another factor key to the adoption of any histological 
biomarker into clinical practice. In the current study, there was a good inter-rater 
weighted kappa value of 0.72 using the ternary scoring system. Unsurprisingly, the 
inter-rater kappa score improved (0.87) when TILHi and TILMod were grouped and 
compared to TILLo. Since a binary TILs scoring system results in greater inter-rater 
correlation without compromising prognostic performance, we recommend that HPV-
associated OpSCC should be classified as TILHi or TILLo using a cut-off value of 20% 
tumour and stroma containing the presence of lymphocytes.  
In summary, we demonstrate the prognostic utility of TILs in HPV-associated OpSCC 
in clinical practice using a binary system where the presence of lymphocytes in 20% 
of tumour and stroma acts as a cut-off to classify HPV-associated OpSCC into high 
and low TILs groups, respectively. Further work, including standardisation of scoring 
criteria, validation in different population cohorts and prospective evaluation of 
recommended cut-offs are necessary prior to implementation of TILs as a criterion 
for treatment selection in de-intensification regimens. 
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Figure legends 
Figure 1. Representative photomicrographs of TILLo (A low power magnification, B 
medium power magnification) and TILHi (C low power magnification, D medium 
power magnification, H&E) HPV-associated OpSCCs. 
 
Figure 2. Kaplan-Meier overall (A, B) and disease-free (C, D) survival plots of HPV-
associated OpSCC the ternary (A, C) and binary (B, D) TILs classification system.  
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